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Summary
Objectives: Most previous studies on the frequency of hepatitis B virus (HBV) and hepatitis C virus
(HCV) have analyzed data obtained from blood donors and risk groups. Few studies have been
conducted in the field in rural and urban areas of Turkey. The aim of this study was to determine
the seroprevalence of HBV and HCV and to investigate the association with risk factors.
Methods: Between January 2006 and March 2007, 2852 people aged 18 years and over were
chosen in three districts using simple random sampling, and blood samples were drawn from
them. The card test technique, which is highly sensitive, was applied to blood samples for the
qualitative assessment of hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antigen
antibodies (anti-HBs), and anti-hepatitis C virus antibodies (anti-HCV). The ELISA technique was
then applied only to positive samples for confirmation. In addition, participants answered survey
questions on risk factors for infection with HBV and HCV.
Results: Our results showed that 71 (2.5%) were HBsAg-positive, 462 (16.2%) were anti-HBs-
positive, and 29 (1.0%) were anti-HCV-positive. Further survey results showed that seropositivity
increased with some of the risk factors.
Conclusions: Studies on seropositivity that depend on field analyses reflect the true population
more accurately. We conclude that such field studies and public education activities for hepatitis
B and C are essential.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +90 246 211 3633;
fax: +90 246 237 1165.
E-mail address: ersinuskun@gmail.com (E. Uskun).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.07.005Introduction
Viral hepatitis is a systemic virus infection characterized by
hepatic cell necrosis and inflammation. The main factors
known to be responsible for the disease are the hepatitis
A, B, C, D, and E viruses.1Published by Elsevier Ltd. All rights reserved.
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diseases transmitted by the parenteral route. There are 400—
500 million carriers of HBV worldwide, with chronic HBV at a
rate of 5%, and it accounts for the etiology of 60—80% of
hepatocellular cancer (HCC) cases.2,3 Hence it is an impor-
tant public health problem. The distribution of HBV infection
shows variations across different geographical areas. Many
studies have been conducted to investigate HBV seropreva-
lence in Turkey, which in this regard shows intermediate
endemicity. In these studies the investigated cases have
frequently been those in risk groups, including healthcare
staff and blood donors.2
Hepatitis C virus (HCV) is considered a serious healthcare
issue all over the world, being the most important cause of
post-transfusion hepatitis. Three hundred million people
worldwide are reported to be infected with HCV. HCV infec-
tions account for 20% of acute hepatitis and 85% of chronic
hepatitis. Acute hepatitis C becomes chronic at a rate of 85%,
and chronic hepatitis C is one of the most common causes of
cirrhosis and HCC.4 The mean frequency of HCV infection in
the world is about 3%.5 Anti-HCV frequency in developed
countries ranges between 1% and 2%.6
Most previous studies on the frequency of HBV and HCV
have analyzed data obtained from blood donors and risk
groups.4 The aim of this study was to determine the sero-
prevalence of HBVand HCV in rural areas of the southwestern
region of Turkey, and to investigate the relationship between
risk factors and the incidence of hepatitis B and C.
Materials and methods
Study population and sampling
The study population consisted of people aged 18 years
living in the villages of Isparta (N = 134 983). Information was
obtained from the Isparta Healthcare Directorship village
clinics and the Private Asylum Population Status Chart. The
study was conducted between January 2006 and March 2007.
The sample size was calculated using INSTAT program in
order to determine HBV and HCV seroprevalence. The sample
size was determined to be 1244 individuals for HBV, at a 99%
confidence interval, with a standard error of 0.02; prevalence
5%, beta = 0.20, and alpha = 0.01. For HCV, it was determined
to be 3989 individuals, at a 99% confidence interval, with a
standard error of 0.005; prevalence 1%, beta = 0.20, and
alpha = 0.01. Hence, the target sample size to determine
HBV and HCV seroprevalence was 3989 individuals.Table 1 Distribution of the study patients among the villages an
Population Distribution of
village population
(%)
Village 1 (18 years of age): 11 223 21%
Village 2 (18 years of age): 21 805 42%
Village 3 (18 years of age): 19 703 37%
Total of three villages
(18 years of age): 52 731
100%
According to recent calculations the total population of all villages in Isp
three villages (those 18 years of age) is 52 731. Number of people inThere is a national health registration system in the health
centers all over Turkey from which data are collected by the
Provincial HealthDirectorate. In this system, thehealth center
staff make a record of every household and individual on
separate cards — the Household Determination Card — so that
every individual has a registration card that holds socio-demo-
graphic information such as age, sex, and educational level.
The target population was calculated by the ratio of the
population aged 18 years (determined by simple random
sampling) to the whole population aged 18 years in three
villages in Isparta (Table 1). Individuals selected by using a
random numbers table of Household Determination Cards
present in the primary healthcare centers at each village,
were invited to the healthcare center for blood analysis. Prior
to study entry, issues regarding the aim of the study, how the
data would be used, and interventions that would be done
were explained to individuals and their written informed
consent was obtained. Questionnaires were given to the
individuals accepting involvement in the study (n = 2852,
71.5%), and blood samples were obtained.
Questionnaires included questions on socio-demographic
characteristics (age, gender, educational status, occupation,
number of people in the same house, monthly income (YTL),
income level, and vaccination for hepatitis B and number of
doses) and risk factors for HBV and HCV infection (having an
accident, having a blood or blood product transfusion, history
of hospitalization, having parenteral drug therapy, intravenous
narcotic druguse, history of hemodialysis treatment, history of
surgery, history of childbirth, having dental treatment, having
circumcision, having ear piercing, having a tattoo (piercing),
being wounded by a contaminated syringe, sexual activity,
contamination with people with HBV or HCV infections or
carriers or with body fluids of any suspected people, having
manicure/pedicure with equipment in common use, razor in
common use, history of shaving with bloodstone, use of com-
mon bathing material or toothbrush, living in crowded areas
with poor sanitary conditions, living with a hepatitis B or C
(jaundice) carrier in the same house, and presence of hepatitis
B or C patient (currently or previously) or carrier in surround-
ings (neighbor, friend, relative, at work, at school, etc.)).
Data collection
Data were collected at the time of blood drawing by ques-
tionnaires prepared by the investigator in order to determine
socio-demographic characteristics and risk factors related to
HBV and HCV infection.d the percentages reached
Target number
of subjects for
the study
Number
reached
Percentage
reached
(row percent)
838 525 62.7%
1676 1402 83.7%
1475 925 62.7%
3989 2852 71.5%
arta (those18 years of age) is 134 983; the total population of the
cluded in the study: 3989.
Table 2 Descriptive characteristics of the study patients
n %a HBsAg-
positive
(ELISA)
Anti-HCV-
positive
(ELISA)
Anti-HBs-
positive (ELISA)
n %b n %b n %b
District
Village 1 525 18.4 22 4.2 1 0.2 80 15.2
Village 2 1402 49.2 21 1.5 21 1.5 213 15.2
Village 3 925 32.4 28 3.0 7 0.8 169 18.3
Gender
Male 967 33.9 31 3.2 8 0.8 147 15.2
Female 1885 66.1 40 2.1 21 1.1 315 16.7
Marital status
Married 2337 81.9 60 2.6 25 1.1 395 16.9
Single 327 11.5 7 2.1 - - 37 11.3
Widow 188 6.6 4 2.1 4 2.1 30 16.0
Educational status
Literate 340 11.9 9 2.6 12 3.5 79 23.2
Not literate 126 4.4 7 5.6 1 0.8 23 18.3
Primary school graduate 1501 52.6 40 2.7 15 1.0 244 16.3
Secondary school graduate 271 9.5 6 2.2 1 0.4 34 12.5
High school graduate 435 15.3 7 1.6 - - * 45 10.3
Senior high school graduate 179 6.3 2 1.1 - - * 37 20.7
Income level
Very low 136 4.8 2 1.5 1 0.7 19 14.0
Low 426 14.9 12 2.8 10 2.3 69 16.2
Moderate 1764 61.9 47 2.7 15 0.9 279 15.8
High 506 17.7 10 2.0 3 0.6 92 18.2
Very high 20 0.7 - - - - 3 15
Total 2852 100.0 71 2.5 29 1.0 462 16.2
*p < 0.001.
a % column.
b % row.
276 F.Z. Akcam et al.For the determination of the seroprevalence of hepatitis B
surface antigen (HBsAg), anti-hepatitis B surface antigen
antibodies (anti-HBs), and anti-hepatitis C virus antibodies
(anti-HCV), 5-ml blood samples were taken from all indivi-
duals answering the questionnaires. After removing the
serum by centrifugation at 5000 rpm for 5 min, these were
analyzed for HBsAg, anti-HBs, and anti-HCV by the card test
method (Acon, San Diego, USA), by which results are rapidly
obtained. For HBsAg and anti-HBs, three drops of serum
sample were applied into the test hole using the dropper
in the test package. This was allowed to stand for 15 min; a
negative result was recorded if only one red line was visible,
appearing in the control (C) zone, while a red line in both the
test zone and the control zone was recorded as a positive
result. For determination of anti-HCV, two drops (80 ml) of
buffer solution were added after dropping 5 ml of serum
sample into the sample hole. This was allowed to stand for
10 min; a negative result was recorded if only one red linewas visible, appearing in the control (C) zone, while a red line
in both the test zone and the control zone was recorded as a
positive result. Blood determined as positive in the card test
was stored at80 8C until further analysis by ELISA. The card
test method has high sensitivity (HBsAg 99%, anti-HCV 100%,
anti-HBs 99%) and high specificity (HBsAg 96.7%, anti-HCV
98.6%, anti-HBs 99%). Positive predictive values are 100% of
anti-HCV while prevalence is 49.8%, 96.6% of HBsAg while
prevalence is 48%, and 99% of anti-HBs while prevalence is
50%. Accuracy is 98.3% for HBsAg, 98.2% for anti-HCV, and 99%
for anti-HBs.
HBsAg, anti-HBs, and anti-HCV were analyzed by ELISA
(Abbott Architect, Abbott Laboratories, IN, USA) in serum
samples with positive results in the card test. Values between
0 and 0.99 mIU/ml were accepted as negative and values
1 mIU/ml were accepted as positive for anti-HCV. Values
between 0 and 0.04 mIU/ml were accepted as negative and
values 0.05 mIU/ml were accepted as positive for HBsAg.
Table 3 Distribution of the study patients according to the parenteral/percutaneous risk factors that result in HBV and HCV
infections
n %a HBsAg-positive (ELISA) Anti-HCV-positive (ELISA)
n %b n %b
Having an accident
Yes 300 10.5 7 2.3 4 1.3
No 2552 89.5 64 2.5 25 1.0
History of blood transfusion
Yes 308 10.8 11 3.6 10 3.2 **
No 2544 89.2 60 2.4 19 0.7
History of hospitalization
Yes 1512 53.0 45 3.0 * 22 1.5 *
No 1340 47.0 26 1.9 7 0.5
History of injections
Yes 989 34.7 35 3.5 ** 14 1.4
No 1863 65.3 36 1.9 15 0.8
Use of intravenous narcotic substance
Yes 24 0.8 1 4.2 1 4.2
No 2828 99.2 70 2.5 28 1.0
History of hemodialysis
Yes 31 1.1 - - 1 3.2
No 2821 98.9 71 2.5 28 1.0
History of surgery
Yes 1071 37.6 29 2.7 20 1.9 **
No 1781 62.4 42 2.4 9 0.5
Childbirth c
Yes 1486 78.8 35 2.4 19 1.3
No 399 21.2 5 1.3 2 0.5
Having dental treatment
Yes 1579 55.4 41 2.6 20 1.3
No 1273 44.6 30 2.4 9 0.7
Having circumcisiond
Yes 793 82.0 21 2.6 6 0.8
No 174 18.0 10 5.7 2 1.1
Ear piercing
Yes 1079 37.8 22 2.0 9 0.8
No 1773 62.2 49 2.8 20 1.1
Having tattoo
Yes 12 0.4 - - 1 8.3
No 2840 99.6 71 2.5 28 1.0
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Table 3 (Continued )
n %a HBsAg-positive (ELISA) Anti-HCV-positive (ELISA)
n %b n %b
Injury by contaminated syringe
Yes 26 0.9 - - 1 3.8
No 2826 99.1 71 2.5 28 1.0
Total 2852 100 71 2.5 29 1.0
*p < 0.05; **p < 0.01.
a % column.
b % row.
c For women only (n = 1885).
d For men only (n = 967).
278 F.Z. Akcam et al.For anti-HBs, values between 0 and 9.99 mIU/ml were
accepted as negative and values 10 mIU/ml were accepted
as positive.
Hypotheses of the study
(1) Hepatitis B and C seroprevalence in the study will be in
concordance with other similar seroprevalence studies in
Turkey. (2) Prevalence will be high in individuals with known
risk factors for hepatitis B and C infection. (3) There is an
association between hepatitis B and C seroprevalence and
some socio-demographic characteristics of the individual and
his/her family.
Statistical analysis
Dependent variables analyzed in the study were HBsAg posi-
tivity, anti-HBs positivity, and anti-HCV positivity, verified by
ELISA following serological tests. The independent variables
analyzed were: age, gender, educational status, occupation,
income level, history of any risk factors for hepatitis B and/or
C infection, having any of the chronic blood disorders, hepa-
titis B vaccination status, and having a hepatitis B and/or C
carrier in the family or among close relatives.
The study data were evaluated by computer using SPSS 9.0
(SPSS Inc., CA, USA). Chi-square, Chi-square for trend, inde-
pendent t-test, Pearson correlation, Spearman correlation,
and regression analyses were used for statistical analysis.
Results
A total of 2852 individuals from three villages of rural Isparta
Province (village 1, n = 525; village 2, n = 1402; village 3,
n = 925) were included in the study; a rate of 71.5% reached.
There were 967 (34%) men and 1885 (66%) women. The mean
age was 42.5  14.4 years and the mean monthly income was
515.8  335.5 YTL. HBsAg positivity was found in 71 (2.5%)
individuals, anti-HBs positivity in 462 (16.2%) individuals, and
anti-HCV positivity in 29 (1.0%) individuals; these were
determined from positive HBsAg, anti-HBs, and anti-HCV
results obtained by the card test method and verified by
ELISA. The distribution of serological indicators according to
descriptive characteristics of the study group, risk factors
related to HBV and HCV infection, and vaccination status are
summarized in Tables 2—5.There was no significant correlation between HBsAg or
anti-HCV positivity and gender or marital status ( p > 0.05).
Anti-HCV positivity (3.2%) was higher in individuals who had
received a blood transfusion than those who had not (0.7%;
Chi-square = 17.059, p = 0.001). HBsAg positivity was higher
in individuals who had been hospitalized (3.0%) than those
who had not (1.9%; Chi-square = 3.140, p = 0.049). Anti-HCV
positivity was higher in individuals who had been hospita-
lized (1.5%) than those who had not (0.5%; Chi-
square = 6.139, p = 0.01). HBsAg positivity was higher in
individuals who had received injections (3.5%) than those
who had not (1.9%; Chi-square = 6.869, p = 0.007). Anti-HCV
positivity was higher in individuals who had undergone
surgery (1.9%) than those who had not (0.5%; Chi-
square = 13.328, p = 0.001). The frequency of anti-HCV posi-
tivity decreased as educational status increased (Chi-square
for trend = 22.161, p = 0.000, p < 0.0001). Anti-HCV posi-
tivity was higher in individuals having contact with a hepa-
titis B or C patient or carrier (4.5%) than those not (0.9%; Chi-
square = 13.958, p = 0.005). HBsAg positivity was higher in
individuals whose mothers are carriers (10.8%) than those
whose mothers are not (2.4%; Chi-square = 10.693,
p = 0.013). Anti-HCV positivity was higher in individuals
having a carrier in the house (3.1%) than those who did
not (0.9%; Chi-square = 8.826, p = 0.012). The mean age of
anti-HCV-positive individuals was higher (57.9  10.2 years)
than those negative (42.3  14.3; p = 0.000).
A significant correlation was found between age (b = 0.97,
95% CI 0.94—0.99, p = 0.017), being male (b = 6.31, 95% CI
1.58—25.16, p = 0.009), and educational status (b = 0.64,
95% CI 0.49—0.84, p = 0.001) and HBsAg positivity when
descriptional properties of the study group (age, gender,
marital status, educational status, income level (YTL), num-
ber of people living in the same house) and infection risk
factors (history of accident requiring hospitalization, having
blood or blood product transfusion, hospitalization, having a
parenteral injection, intravenous narcotic drug use, having
hemodialysis treatment, history of surgery, history of child-
birth, having dental treatment, having circumcision, having
ear piercing, having tattoo (piercing), being wounded by a
contaminated syringe, sexual life characteristics, hepatitis B
patient, contact with body fluids of a carrier, having mani-
cure/pedicure with equipment in common use, razor in
common use, shaving with bloodstone, use of common bath-
ing material or toothbrush, living in crowded places like
nursing house or boarding school, etc., living in poor sanitary
Table 4 Distribution of the study patients according to other risk factors that result in HBV and HCV infections
n %a HBsAg-positive
(ELISA)
Anti-HCV-positive
(ELISA)
n %b n %b
Sexual experiencec
No sexual experience 230 8.9 4 1.7 - -
Not married but have sexual experience 92 3.6 2 2.2 - -
Married and have no other sexual experience 2220 86.1 58 2.6 23 1.0
Married and have sexual experience other than
his/her husband/wife
36 1.4 2 5.6 - -
Contact with hepatitis B or C patient or carrier
Yes 111 3.9 6 5.4 5 4.5 **
No 2741 96.1 65 2.4 24 0.9
Manicure/pedicure with equipment in common use
Yes 44 1.5 1 2.3 - -
No 2808 98.5 70 2.5 29 1.0
Shaving with equipment in common use
Yes 217 7.6 9 4.1 3 1.4
No 2635 92.4 62 2.4 26 1.0
Using bathing material, toothbrush in common use
Yes 361 12.7 9 2.5 1 0.3
No 2491 87.3 62 2.5 28 1.1
Living in crowded places
Yes 181 6.3 6 3.3 1 0.6
No 2671 93.7 65 2.4 28 1.0
Living in crowded areas with poor sanitary conditions
Yes 113 4.0 3 2.7 2 1.8
No 2739 96.0 68 2.5 27 1.0
Living with a hepatitis B, C carrier in the same house
Yes 195 6.8 8 4.1 6 3.1 *
No 2657 93.2 63 2.4 23 0.9
Having a hepatitis B, C carrier among neighbors and relatives
Yes 228 8.0 10 4.4 3 1.3
No 2624 92.0 61 2.3 26 1.0
Mother being a hepatitis B, C carrier
Yes 37 1.3 4 10.8 * 1 2.7
No 2815 98.7 67 2.4 28 1.0
Having any known blood disorders
Yes 21 0.7 - - 1 4.8
No 2831 99.3 71 2.5 28 1.0
Total 2852 100 71 2.5 29 1.0
*p < 0.05; **p < 0.01.
a % column.
b % row.
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Table 5 Hepatitis B vaccination status of the study patients
n % HBsAg-
positive
(ELISA)
n %
Vaccination status
Vaccinated 120 4.2 3 2.5
Not vaccinated 2732 95.8 68 2.5
Vaccination dose
One dose 11 9.2 - -
Two doses 28 23.3 1 3.6
Three or more doses 46 38.3 1 2.2
Do not remember 35 29.2 1 2.9
Total (n = 2852) 120 4.2 3 0.1
The time from last hepatitis B vaccination in the vaccinated group
was determined as 49.7  36.5 months (range 2—135 months).
280 F.Z. Akcam et al.conditions, living with a carrier, presence of hepatitis B
carrier in close surroundings (neighbor, friend, relative, at
work, etc.), mother being a hepatitis B patient or carrier,
having a known blood disorder) were taken into a multiple
regression model (Table 6).
A significant correlation was found between age (b = 1.08,
95% CI 1.03—1.13, p = 0.0007), having a blood or blood
product transfusion (b = 6.62, 95% CI 2.20—19.91,
p = 0.0007), and history of parenteral injection (b = 0.28,
95% CI 0.08—0.92, p = 0.036) and anti-HCV positivity when
descriptional properties of the study group (age, gender,
marital status, educational status, income level (YTL), num-
ber of people living in the same house) and infection risk
factors (history of accident requiring hospitalization, having
a blood or blood product transfusion, hospitalization, having
a parenteral injection, intravenous narcotic drug use, having
hemodialysis treatment, history of surgery, history of child-
birth, having dental treatment, having circumcision, having
ear piercing, having tattoo (piercing), being wounded by a
contaminated syringe, sexual life characteristics, hepatitis C
patient, contact with body fluids of a carrier, having mani-
cure/pedicure with equipment in common use, razor in
common use, shaving with bloodstone, use of common bath-
ing material or toothbrush, living in crowded places like
nursing house, boarding school, etc., living in poor sanitary
conditions, living with a hepatitis C carrier, presence of
hepatitis C carrier in close surroundings (neighbor, friend,
relative, at work, etc.), mother being a hepatitis C patient or
carrier, having a known blood disorder) were taken into a
multiple regression model (Table 7).
Discussion
The distribution of HBV infection across the world shows
variations depending on geographical location. According to
these variations, the world can be divided into low, medium,
and high endemicity zones. In zones where endemicity is low,
the prevalence of being an HBV carrier is <2%; in medium
endemicity zones, this is between 2% and 10%, while it is>10%
in high endemicity zones. HBsAg seroprevalence has beenfound to vary between 3.9% and 12.5% in studies conducted
on various groups in our country.2,7 Thus, Turkey is a medium
endemicity zone with regard to hepatitis B.
To date, most of the studies investigating HBsAg preva-
lence in normal populations excluding donors have been
performed in adults living in cities. In some of the few studies
involving cases from both urban and rural areas, no significant
difference was observed regarding seropositivity; in others it
was found that HBsAg seropositivity was lower in rural areas,
while still others reported that HBsAg seropositivity was
higher in rural areas. Looking at the overall results of these
studies, the frequency of HBsAg was found to vary between
1.1% and 12.4%, indicating that more detailed research on
this issue is still required.8
Anti-HBs positivity in our country varies between 20.6%
and 52.3% in studies investigating the presence of anti-HBs.8
Anti-HBs positivity was seen in 8094 people (29.7%) in studies
conducted on normal people.9
In Turkey, the frequency of HCV varies between 1.2% and
4%. Anti-HCV frequency was reported to be 0.05% in blood
donors and 51.6% in hemodialysis patients. The ranges for
blood donors do not generally exceed 1%.10 According to the
verified results of this study, in which the rates of HBsAg,
anti-HCV, and anti-HBs were determined, the frequencies of
HBsAg and anti-HBs were found to be lower than the mean
value in our country and that for anti-HCV complied with the
mean. A routine vaccination program for hepatitis B was
initiated in 1998 in Turkey. We think that the low vaccination
rate (4.2%) in the adult population above 18 years of age and
the low anti-HBs frequency (16.2%) in this study might also
be related, thus more attention should be given to public
education.
There have been few studies conducted in rural and/or
urban areas in our country. In a study conducted by Dursun
et al., HBsAg seroprevalence and risk factors were investi-
gated in 2888 subjects in rural and urban areas of four cities
in the southeastern Anatolian zone using the group sampling
method. HBsAg frequency was determined as 8.2% in rural
areas and 6.2% in urban areas. In urban areas the risk factor
was determined to be low educational level, and having a
history of jaundice in the family was determined to be a risk
factor in rural areas.11 According to the verified results of our
study, the frequency of HBsAg was determined as 2.5%, and
factors increasing HBsAg frequency in the univariate analysis
were hospitalization, having injections, and mother being a
carrier. In multivariate analysis, HBsAg frequency was found
to be high in males and was negatively correlated with
educational level.
In another study by Karabay et al. investigating the
prevalence of being a hepatitis B carrier in urban and rural
areas of Bolu Province, a total of 5234 cases (n = 4084 in
urban areas and n = 1150 in rural areas) were included. The
rate of being an HBsAg carrier was found to be 2.85% in urban
areas and 2.6% in rural areas.12 The rate of being an HBsAg
carrier in rural areas is similar to the frequency we have
found.
In Denmark and England, the most common transmission
route of HBV has been reported to be in the use of intravenous
narcotic drugs.13,14 In a study reported from Thailand, on the
other hand, anti-HCV positivity, reported to be 0.98% in blood
donors, was found to be 17—20% in drug addicts.15 The
prevalence of anti-HCVamong injecting drug users compared
Table 6 Results of the multiple logistic regression analysis for HBsAg positivity with descriptive properties of the study group and
frequency of encountering conditions carrying a risk for infection with HBV
p Beta 95% CI
Age 0.017 0.97 0.94—0.99
Gender (male) 0.009 6.31 1.58—25.16
Marital status
Married (reference)
Single 0.218 2.91 0.52—16.04
Widow 0.747 1.28 0.27—5.96
Educational status 0.001 0.64 0.49—0.84
Number of people living in the same house 0.183 1.09 0.95—1.26
Income level (YTL) 0.820 0.99 0.99—1.00
History of having an accident requiring hospitalization 0.342 0.66 0.28—1.54
Having blood or blood product transfusion 0.433 1.34 0.64—2.80
History of hospitalization 0.433 1.34 0.64—2.79
History of parenteral injection 0.09 1.76 0.91—3.42
Intravenous narcotic drug use 0.572 1.83 0.22—15.18
History of hemodialysis 0.758 <0.01 0.00—<0.01
History of surgery 0.594 0.84 0.46—1.55
History of childbirth 0.474 1.55 0.46—5.19
History of dental treatment 0.343 1.29 0.75—2.21
History of circumcision 0.064 0.45 0.19—1.04
History of ear piercing 0.856 0.93 0.48—1.83
History of having tattoo, piercing 0.837 <0.01 0.00—<0.01
History of being wounded by contaminated syringe 0.732 <0.01 0.00—<0.01
Sexual experience
No sexual experience (reference)
Not married but have active sexual experience 0.678 0.67 0.10—4.36
Married, having sex only with his/her husband/wife 0.257 3.14 0.43—22.82
Married, also have sexual experience outside marriage 0.196 5.16 0.42—62.46
History of contact with body fluids of a
hepatitis B patient/carrier
0.639 1.30 0.43—3.89
History of having manicure/pedicure with
equipment in common use
0.919 0.88 0.08—9.65
History of use of common razor, shaving with bloodstone 0.413 1.42 0.60—3.33
History of use of common bathing material or toothbrush 0.552 0.78 0.35—1.73
History of living in crowded places like nursing
house, boarding school, etc.
0.638 1.28 0.44—3.71
History of living in poor sanitary conditions 0.809 0.84 0.21—3.30
History of living with a hepatitis B carrier 0.744 1.17 0.44—3.08
Presence of hepatitis B carrier in close surroundings
(neighbor, friend, relative, at work, etc.)
0.205 1.73 0.73—4.08
Mother having history of a hepatitis B disease or
status of being carrier
0.066 3.32 0.91—12.00
Having a known blood disorder 0.807 <0.01 0.00—<0.01
CI, confidence interval.
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most European countries injecting drug use is the major
source of new infections, and HCV prevalence in these
populations has been found to be high (48—90%); this popula-
tion is an important reservoir of the disease.16 In our study,
while a correlation was found between narcotic drug use and
HCV, no such correlation was observedwith HBV. However, we
detected in our study that the number of people using
intravenous narcotic drugs was low, and thus there was onlyone case with HBsAg positivity and one with HCV positivity.
This leads to wider confidence intervals in terms of risk, and
thus to less reliable results. To obtain amore accurate picture
of this, further studies on those using narcotics in larger
populations should be performed.
In a multicenter study from Brazil, HBV and HCV preva-
lence were found to increase with age in blood donors.17 In
our study, a similar correlation was found between age and
HBV and HCV seroprevalence.
Table 7 Results of the multiple logistic regression analysis for anti-HCV positivity with descriptive properties of the study group
and frequency of encountering conditions carrying a risk for infection with HCV
p Beta 95% CI
Age <0.001 1.08 1.03—1.13
Gender (male) 0.293 4.12 0.29—57.99
Marital status
Married (reference)
Single 0.849 <0.01 0.00—<0.01
Widow 0.317 0.30 0.02—3.15
Educational status 0.083 0.62 0.37—1.06
Number of people living in the same house 0.665 1.05 0.82—1.35
Income level (YTL) 0.274 0.99 0.99—1.00
History of having an accident requiring hospitalization 0.836 0.86 0.20—3.55
Having blood or blood product transfusion <0.001 6.62 2.20—19.91
History of hospitalization 0.575 0.67 0.17—2.66
History of parenteral injection 0.036 0.28 0.08—0.92
Intravenous narcotic drug use 0.944 <0.01 0.00—<0.01
History of hemodialysis treatment 0.988 0.97 0.05—17.06
History of surgery 0.088 2.93 0.84—10.16
History of childbirth 0.323 2.96 0.34—25.76
History of dental treatment 0.188 2.05 0.70—6.01
History of circumcision 0.334 0.41 0.06—2.50
History of ear piercing 0.271 0.53 0.17—1.62
History of having tattoo, piercing 0.178 18.02 0.26—1220.54
History of being wounded by contaminated syringe 0.287 5.98 0.22—161.77
Sexual experience
No sexual experience (reference)
Not married but have active sexual experience 0.967 0.06 0.00—<0.01
Married, having sex only with his/her husband/wife 0.916 37.79 0.00—<0.01
Married, also have sexual experience outside marriage 0.969 0.02 0.00—<0.01
History of contact with body fluids of a hepatitis
C patient or carrier
0.661 1.50 0.24—9.40
History of having manicure/pedicure with
equipment in common use
0.944 <0.01 0.00—<0.01
History of use of common razor, shaving with bloodstone 0.772 0.71 0.07—6.80
History of use of common bathing material or toothbrush 0.253 0.24 0.02—2.73
History of living in crowded places like nursing house,
boarding school, etc.
0.783 0.67 0.04—10.67
History of living in poor sanitary conditions 0.064 6.22 0.89—43.18
History of living with a hepatitis C carrier 0.155 3.46 0.62—19.28
Presence of hepatitis C carrier in close surroundings
(neighbor, friend, relative, at work, etc.)
0.258 2.41 0.52—11.08
Mother having history of hepatitis C disease or
status of being carrier
0.468 2.50 0.20—29.83
Having a known blood disorder 0.452 4.13 0.10—167.80
CI, confidence interval.
282 F.Z. Akcam et al.Although some studies have suggested that HCV seropo-
sitivity is strongly associated with male sex, non-white eth-
nicity,18 and greater age,18,19 in this study, no significant
correlation was found between anti-HCV seropositivity and
age, gender, or socio-economic status. According to the
verified results of our study, anti-HCV frequency was deter-
mined as 1.0%, and factors increasing anti-HCV frequency in
the univariate analysis were having a blood transfusion,
hospitalization, having surgery, low educational level, his-
tory of contact with a hepatitis C patient, living with a carrierin the same house, and older age. In the multivariate ana-
lysis, anti-HCV frequency was found to increase with increas-
ing age and blood/blood product transfusions.
According to the true positive values obtained in ELISA
tests performed for confirmation in those cases that had
positive card test results, the positive predictive value of
the card test was 89% for HBsAg and 71% for anti-HCV
(Table 8). As no confirmation tests could be performed for
cases with negative card test results, the number of cases
with true negative results could not be detected, thus the
Table 8 Distribution of the study patients according to
hepatitis B and hepatitis C card test and ELISA data
Total Positive sample
n %
Card test HBsAg 2852 80 2.8
Card test anti-HCV 2852 41 1.4
Card test anti-HBs 2852 517 18.1
ELISA HBsAg 80 71 88.8
ELISA anti-HCV 41 29 70.7
ELISA anti-HBs 514a 462 89.9
a Three blood samples were not included in the analyses as they
were not appropriate.
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values are largely affected by the disease prevalence. The
positive predictive value increases as prevalence increases,
and decreases as prevalence decreases. As both hepatitis B
and hepatitis C prevalence were low in the study population,
the low positive predictive values detected were expected.
There were some limitations of the study: (1) not being
able to verify negative card test results by ELISA; (2) reaching
only 71.5% of the targeted population; (3) the accuracy of the
data depends on the study subject’s declarations, since data
collection was achieved by a questionnaire.
This was a population-based study performed by using
sampling with the probability method. Not being able to
verify negative card test results due to the costs is a limita-
tion of our study. However, low-cost methods with high
sensitivity are preferred in studies conducted by diagnostic
tests. We have also used the card test method, which has a
high sensitivity and specificity. Another limitation of our
study is that we reached only 71.5% of the targeted popula-
tion. It is possible that invited individuals did not participate
because they found blood drawing to be invasive. Individuals
who knew that they were carriers might not have partici-
pated because of confidentiality concerns, since an infec-
tious disease would be detected after examination and
because they would not want to be known to have the
disease. Therefore the frequency we have found may not
reflect the real situation.
Another limitation is that the accuracy of the data regard-
ing risk factors in our study depends on the individuals’ own
responses to the questionnaire. Answering questions related
to risk factors such as sexual preference and narcotic drug
use might be affected by socio-cultural factors.
Conclusions and recommendations
Studies on HBVand HCV seroprevalence in Turkey havemostly
been conducted in risk groups and donors. There have been
few studies performed on healthy populations in both rural
and urban areas. We believe that this area of study is of
importance. Broad research studies should be conducted in
order to determine hepatitis B vaccination status in the adult
population and an immunization program should be initiated
for non-vaccinated adults. We believe that it is necessary to
give more importance to educational activities to inform the
public about the infection routes and risk factors for hepatitis
B and C infections.Acknowledgement
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